Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Supreme Court Allows Maine Rx; PhRMA Says States Will Delay Similar Plans

Executive Summary

The Pharmaceutical Research & Manufacturers of America believes that until Maine issues regulations to implement Maine Rx, other states will wait before proceeding with similar programs

You may also be interested in...



State Rx Rebates For Non-Medicaid Populations Backed By Kerry

The administration of Democratic presidential nominee John Kerry would support using Medicaid prior authorization lists to obtain drug rebates for non-Medicaid populations

State Rx Rebates For Non-Medicaid Populations Backed By Kerry

The administration of Democratic presidential nominee John Kerry would support using Medicaid prior authorization lists to obtain drug rebates for non-Medicaid populations

Michigan Rx rebate requirements upheld

Michigan Medicaid may require prior authorization for drugs that do not provide rebates to non-Medicaid programs, D.C. federal appeals court affirms April 2. The Pharmaceutical Research & Manufacturers of America's lawsuit against the state argued the policy was not in the "best interest" of Medicaid recipients; the lower court also ruled against PhRMA (1"The Pink Sheet" March 31, 2003, In Brief). The 2appellate court ruling cited the Supreme Court's rejection of PhRMA's challenge to a similar Maine program last year (3"The Pink Sheet" May 26, 2003, p. 23). [Editor's Note: A version of this story first appeared in 4"The Pink Sheet" DAILY April 2. Visit our website, www.ThePinkSheetDAILY.com, to sign up for a free trial.]...

Related Content

UsernamePublicRestriction

Register

PS041873

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel